# A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07736612/  
OnCo record `nct07736612` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of nimotuzumab, HS-20093 and adebrelimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.

## Summary

A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07736612 by Zhejiang University, with a registry enrolment figure of 80 participants, started 2026-08-15 and due to reach its primary completion in 2028-08-30. Interventions recorded: HRS-2329 Tablet; Nimotuzumab; HS-20093; Adebrelimab. Conditions listed: Pancreatic Cancer; RAS Mutations or Amplifications. Primary outcome: Objective Response Rate. Pancreatic eligibility wording from the registry: "* Histopathologically confirmed locally advanced or metastatic pancreatic adenocarcinoma (originating from pancreatic ductal epithelium) that is not amenable to curative therapy". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07736612
- Phase: 1/2
- Setting: A Phase Ib/II Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
- Sponsor: Zhejiang University
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07736612: https://clinicaltrials.gov/study/NCT07736612

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [HS-20093](https://onco.cc/drugs/hs-20093/), [Nimotuzumab](https://onco.cc/drugs/nimotuzumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07736612.json